EN DE
STOCK COMPARISON

Aurobindo Pharma vs Jiangsu Hengrui Medicine Co: Fair Value & Quality

Both stocks run through our valuation models. Here is how Aurobindo Pharma (AUROPHARMA) and Jiangsu Hengrui Medicine Co (600276) compare, as of Aug 8, 2026.

As of Aug 8, 2026, Fair Value Calculator sees Aurobindo Pharma as the less overvalued of the two: Aurobindo Pharma trades at ₹1,589 versus a fair value of ₹1,340 (-16%), while Jiangsu Hengrui Medicine Co trades at ¥52.11 versus ¥25.94 (-50%).
Aurobindo Pharma
AUROPHARMA.NSE · INR · Health Care
-16%
upside to fair value
overvalued
Price₹1,589
Fair Value₹1,340
Quality66/100
Jiangsu Hengrui Medicine Co
600276.SHG · CNY · Health Care
-50%
upside to fair value
overvalued
Price¥52.11
Fair Value¥25.94
Quality59/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Aurobindo PharmaJiangsu Hengrui Medicine Co
Valuation
25.7×P/E (TTM)43.6×
2.65×P/S (TTM)10.84×
2.35×P/B5.76×
11.7×EV/EBITDA33.0×
—PEG0.93×
—Dividend yield0.4%
—Dividend per share¥0.20
Profitability
10%Net margin25%
15%Operating margin32%
10%Return on equity15%
6%Return on assets9%
Growth
6%Revenue growth (YoY)13%
10.6%Avg. growth/yr (3Y)13.9%
6.3%Avg. growth/yr (5Y)2.5%
Balance & size
0.02×Debt / equity—
$9BMarket cap$52B
healthyGrowth qualityhealthy

Jiangsu Hengrui Medicine Co leads: 5 to 6 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Aurobindo Pharmaof which business quality 58 · market factors 83 Jiangsu Hengrui Medicine Coof which business quality 68 · market factors 42
ProfitabilityMargins and returns on capital today
43
63
Quality GrowthAre margins and returns improving?
32
41
CashflowEarnings quality: real cash, not paper profit
51
82
Fin. StrengthBalance sheet, leverage, solvency risk
87
100
InvestmentDisciplined investing over empire-building
46
27
Low VolatilityCalm price path (market factor)
88
78
MomentumPrice trend over the last 3–12 months (market factor)
75
30
52W MomentumDistance to the 52-week high (market factor)
88
23
Net IssuanceBuybacks instead of dilution
85
64

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Aurobindo Pharma

DCF Models₹1,549
Earnings-Based₹814
Dividend Discount₹77.15
Multiples₹1,262
Asset-Based₹441
Growth DCF₹1,468
Economic Profit₹860
Growth Earnings₹1,157

20 of 26 models see the stock below the current price.

Jiangsu Hengrui Medicine Co

DCF Models¥37.11
Earnings-Based¥21.29
Dividend Discount¥3.82
Multiples¥22.37
Asset-Based¥6.44
Growth DCF¥38.47
Economic Profit¥18.21
Growth Earnings¥29.68

26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Aurobindo Pharma
Bear ₹1,005Fair Value ₹1,340Bull ₹1,675
₹1,589 = current price (white tick)
Jiangsu Hengrui Medicine Co
Bear ¥19.95Fair Value ¥25.94Bull ¥40.28
¥52.11 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Aurobindo Pharma · Health Care

Quality score66 · Top 25%
Fair value upside-16% · above median

Jiangsu Hengrui Medicine Co · Health Care

Quality score59 · Top 25%
Fair value upside-50% · below median

Bottom line

As of Aug 8, 2026, Fair Value Calculator sees Aurobindo Pharma as the less overvalued of the two: Aurobindo Pharma trades at ₹1,589 versus a fair value of ₹1,340 (-16%), while Jiangsu Hengrui Medicine Co trades at ¥52.11 versus ¥25.94 (-50%).

Aurobindo Pharma has the higher quality score (66/100).

See the full analysis →
Aurobindo Pharma · Jiangsu Hengrui Medicine Co

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Aurobindo Pharma

Eli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth GroupUnitedHealth Group vs Merck & Company

Related to Jiangsu Hengrui Medicine Co

UnitedHealth Group vs AstraZenecaUnitedHealth Group vs Thermo Fisher ScientificUnitedHealth Group vs AmgenUnitedHealth Group vs Abbott Laboratories
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.